The MarketReader Minute
Among the ETF's holdings, significant contributors include REGN, VRTX, MTD, MRNA, and GILD, all showing positive returns. Additionally, the Russell 2000 Index has increased by 1.17%, reflecting broader market sentiment that often impacts the biotechnology sector.
The MarketReader Minute
Among the ETF's holdings, Moderna reported a significant drop in first-quarter revenues, contributing negatively to IBB's performance. Regeneron Pharmaceuticals is set to present new oncology data at the 2025 ASCO Annual Meeting, coinciding with a lowered price target from Guggenheim.
The MarketReader Minute
(IBB) has seen a price movement of -0.3% since Friday. In terms of performance among holdings, significant contributors included MRNA, BIIB, NBIX, BPMC, and INSM, all of which posted negative returns.
The MarketReader Minute
(IBB) has experienced a decline of 2.5% during Monday's trading session, coinciding with significant downturns in the broader U.S. stock market. Major indices are falling sharply due to concerns over President Trump's upcoming reciprocal tariffs, which are expected to take effect on April 2nd.
The MarketReader Minute
Bank of Canada announced a reduction in its target overnight rate by 25 basis points due to heightened trade tensions from new U.S. tariffs, influencing market sentiment regarding economic stability, which may negatively impact healthcare equities like the iShares Biotechnology ETF (IBB).
The MarketReader Minute
Key holdings within IBB have also faced losses, including Vertex Pharmaceuticals and Moderna, both of which contributed negatively to the ETF's performance.
The MarketReader Minute
Among the ETF's holdings, BioNTech SE reported a net profit for Q4 2024 that was lower than the previous year, alongside total revenue that fell short of prior estimates
The MarketReader Minute
(IBB) has seen a price movement of -0.5% since Friday. Among the ETF's holdings, Fortrea Holdings reported fourth-quarter financials that fell short of expectations, contributing to negative performance from several key stocks.
The MarketReader Minute
Within IBB's holdings, Iovance Biotherapeutics faced a substantial decline due to negative analyst revisions despite reporting a narrower Q4 net loss. Intellia Therapeutics also saw significant downgrades from analysts, while Apellis Pharmaceuticals reported strong Q4 results.
The MarketReader Minute
Among IBB's holdings, significant declines were noted for Vertex Pharmaceuticals, IQVIA, Alnylam Pharmaceuticals, Myriad Genetics, and Natera, with Myriad Genetics experiencing a notable drop following a fourth-quarter earnings report that missed revenue expectations.
The MarketReader Minute
Among the ETF's holdings, notable contributors to performance included MTD, NTRA, REGN, MRNA, and UTHR, all experiencing declines. Furthermore, the Russell 2000 Index has also declined, reflecting broader market sentiment that could influence IBB's stability.
The MarketReader Minute
Among the ETF's holdings, BioMarin Pharmaceutical Inc. reported strong fourth-quarter results, exceeding earnings estimates significantly and raising analysts' price targets. Additionally, the AUD/USD currency pair has increased, reflecting broader market movements that may also influence IBB.
